Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
On Feb. 16, 2023, it was reported in the Lancet that protection from past infection against re-infection from…
On Feb. 15, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced a major step forward…
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
On Feb. 14, 2023, scientists from the National Institute of Allergy and Infectious Diseases announced they had developed…
On Feb. 13, 2023, Novavax announced a modification to its existing agreement with the U.S. Department of Health…
On Feb. 8, 2023, as bird flu continues to circle the globe, a new report suggested that the…
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
On Feb. 2, 2023, a National Institutes of Health research group with extensive experience studying ebolavirus countermeasures successfully…
On Jan. 26, 2023, Centers for Disease Control and Prevention (CDC) reported that U.S. household spread of flu…
On Jan. 25, 2023, researchers at Oregon Health & Science University (OHSU) reported that Immunity from COVID-19 appears…
On Jan. 18, 2023, Novavax announced that partner SK bioscience had received expanded manufacturing and marketing approval from…
On Jan. 18, 2023, the National Institutes of Health (NIH) announced that an investigational HIV vaccine regimen tested…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Jan. 11, 2023, Roche announced treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis…
On Jan. 11, 2023, the U.S. Food and Drug Administration reported that a single booster dose with an…
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
Milestones in Polio illustrates the slow but steady advancements from its clinical description and discovery to widespread infection…
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
On Nov. 12, 2022, the World Health Organization (WHO) issued a Disease Outbreak News (DON) on the circulating…
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Dec. 15, 2022, the University of Oxford Oxfordï¾’s Ebola vaccine candidate has been shipped to Uganda, just…
On Dec. 14, 2022, the National Institutes of Health announced that two randomized, placebo-controlled trials evaluating three Ebola…
On Dec. 12, 2022, the Oregon Department of Agriculture and the U.S. Department of Agriculture’s Animal Plant Health…
On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite…
On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….